Decision Resources, Inc., one of the world's leading research and advisory firms for pharmaceutical and health care issues, finds that physicians and managed care pharmacy directors disagree on the use of fixed-dose combination agents for the treatment of metabolic syndrome. According to a new PhysicianForum report entitled Metabolic Syndrome in the United States: Current Medical Practice and Market Opportunities, approximately 90% of physicians surveyed would prescribe these drugs to patients with metabolic syndrome, but only 57% of managed care pharmacy directors would favor their reimbursement.
An example of a fixed-dose drug therapy for metabolic syndrome that will encounter challenges is Pfizer's Caduet, a fixed-dose combination of atrovastatin and amlodipine that reached the market in 20004 for the treatment of hypertension and dyslipidemia, two major components of the syndrome.
"High-prescribing primary care physicians (PCPs) are enthusiastic about Caduet and would prescribe it even in patients with borderline hypertension or dyslipidemia," said Carole Gleeson, analyst at Decision Resources. "However, 33% of surveyed cardiologists would not prescribe Caduet because of the various limitations of fixed-dose combination agents. Reimbursement issues will haunt Caduet as well, as indicated by the divided opinions of surveyed managed care pharmacy directors."
Metabolic Syndrome in the United States: Current Medical Practice and Market Opportunities is based on a survey of 17 HMO pharmacy directors, 71 primary care physicians, 136 endocrinologists, and 50 cardiologists throughout the United States. Their responses were compared to assess similarities and differences in clinical, economic, and scientific factors.
About Metabolic Syndrome
Metabolic syndrome is a constellation of metabolic abnormalities that are associated with increased risk for cardiovascular disease. These metabolic abnormalities include glucose intolerance, insulin resistance, obesity, type 2 diabetes, dyslipidemia, and hypertension.
PhysicianForum is a new primary research service from Decision Resources. The service offers access to high volume-prescribing PCPs, specialists, and managed care organization representatives in the United States; analysis of events and survey participants' responses to them; insight into prescribing patterns; and an examination of the implications for the pharmaceutical market.
About Decision Resources
Decision Resources, Inc., (http://www.decisionresources.com/) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact: Elizabeth Marshall Decision Resources, Inc. 781-296-2563 firstname.lastname@example.org
SOURCE: Decision Resources, Inc.
CONTACT: Elizabeth Marshall of Decision Resources, Inc., +1-781-296-2563,
Web site: http://www.decisionresources.com/